Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jan;63(1):17–28. doi: 10.1038/bjc.1991.7

Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines.

K Snow 1, W Judd 1
PMCID: PMC1971666  PMID: 1989661

Abstract

Cell lines resistant to adriamycin and amsacrine were derived from cloned sublines of the human T cell line Jurkat. Most of the lines resemble atypical MDR cells (Danks et al., 1987; Beck et al., 1987). Thus, resistant Jurkat sublines were cross resistant to several topoisomerase II inhibiting drugs but had low or no resistance to other classes of drugs, resistance was not reversed by verapamil, Pgp was not overexpressed, and drug accumulation was unaltered in resistant compared to parental (control) sublines. Other findings were that anthracycline metabolism differed between resistant and parental sublines, and that resistant sublines displayed altered expression of small polypeptides (less than 20K MW) and an 85K MW protein. Drug resistant cells showed resistance to the production of drug induced cytogenetic aberrations, DNA breaks, and protein-DNA complexes. Resistance was not mediated by altered binding of drugs to DNA or by increased repair of DNA damage. Indirect evidence suggests that the resistant cells had an altered drug-DNA-topoisomerase II association. The study highlights the complex relationships between DNA breaks, cytogenetic aberrations, protein-DNA complexes and drug cytotoxicity, and shows that the relationships differ for adriamycin and amsacrine, suggesting some differences in the modes of action and/or resistance for the drugs and cell lines.

Full text

PDF
17

Images in this article

20Figure 2
on p.20
21Figure 3
on p.21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebi H. Catalase in vitro. Methods Enzymol. 1984;105:121–126. doi: 10.1016/s0076-6879(84)05016-3. [DOI] [PubMed] [Google Scholar]
  2. Ahmed N. K. Daunorubicin reductase activity in human normal lymphocytes, myeloblasts and leukemic cell lines. Eur J Cancer Clin Oncol. 1985 Oct;21(10):1209–1213. doi: 10.1016/0277-5379(85)90017-3. [DOI] [PubMed] [Google Scholar]
  3. Ahmed N. K., Felsted R. L., Bachur N. R. Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochem Pharmacol. 1978;27(23):2713–2719. doi: 10.1016/0006-2952(78)90047-3. [DOI] [PubMed] [Google Scholar]
  4. Akerboom T. P., Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol. 1981;77:373–382. doi: 10.1016/s0076-6879(81)77050-2. [DOI] [PubMed] [Google Scholar]
  5. Andersson B. S., Beran M., Barlogie B., Van N. T., McCredie K. B. Analysis of nuclear m-AMSA content by DNA fluorochrome competition. Eur J Cancer Clin Oncol. 1986 Jul;22(7):883–889. doi: 10.1016/0277-5379(86)90378-0. [DOI] [PubMed] [Google Scholar]
  6. Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984 Oct;44(10):4224–4232. [PubMed] [Google Scholar]
  7. Beauchamp C., Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem. 1971 Nov;44(1):276–287. doi: 10.1016/0003-2697(71)90370-8. [DOI] [PubMed] [Google Scholar]
  8. Beck W. T., Cirtain M. C., Danks M. K., Felsted R. L., Safa A. R., Wolverton J. S., Suttle D. P., Trent J. M. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells. Cancer Res. 1987 Oct 15;47(20):5455–5460. [PubMed] [Google Scholar]
  9. Beck W. T. The cell biology of multiple drug resistance. Biochem Pharmacol. 1987 Sep 15;36(18):2879–2887. doi: 10.1016/0006-2952(87)90198-5. [DOI] [PubMed] [Google Scholar]
  10. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  11. Bradley G., Juranka P. F., Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1988 Aug 3;948(1):87–128. doi: 10.1016/0304-419x(88)90006-6. [DOI] [PubMed] [Google Scholar]
  12. Carlberg I., Mannervik B. Glutathione reductase. Methods Enzymol. 1985;113:484–490. doi: 10.1016/s0076-6879(85)13062-4. [DOI] [PubMed] [Google Scholar]
  13. Cowan K. H., Batist G., Tulpule A., Sinha B. K., Myers C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9328–9332. doi: 10.1073/pnas.83.24.9328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Curt G. A., Clendeninn N. J., Chabner B. A. Drug resistance in cancer. Cancer Treat Rep. 1984 Jan;68(1):87–99. [PubMed] [Google Scholar]
  15. Dalton W. S., Durie B. G., Alberts D. S., Gerlach J. H., Cress A. E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res. 1986 Oct;46(10):5125–5130. [PubMed] [Google Scholar]
  16. Danks M. K., Yalowich J. C., Beck W. T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 1987 Mar 1;47(5):1297–1301. [PubMed] [Google Scholar]
  17. Dodion P., Bernstein A. L., Fox B. M., Bachur N. R. Loss of fluorescence by anthracycline antibiotics: effects of xanthine oxidase and identification of the nonfluorescent metabolites. Cancer Res. 1987 Feb 15;47(4):1036–1039. [PubMed] [Google Scholar]
  18. Fairchild C. R., Ivy S. P., Kao-Shan C. S., Whang-Peng J., Rosen N., Israel M. A., Melera P. W., Cowan K. H., Goldsmith M. E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987 Oct 1;47(19):5141–5148. [PubMed] [Google Scholar]
  19. Ferro-Luzzi Ames G. The basis of multidrug resistance in mammalian cells: homology with bacterial transport. Cell. 1986 Nov 7;47(3):323–324. doi: 10.1016/0092-8674(86)90585-4. [DOI] [PubMed] [Google Scholar]
  20. Finlay G. J., Baguley B. C., Snow K., Judd W. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. J Natl Cancer Inst. 1990 Apr 18;82(8):662–667. doi: 10.1093/jnci/82.8.662. [DOI] [PubMed] [Google Scholar]
  21. Flohé L., Günzler W. A. Assays of glutathione peroxidase. Methods Enzymol. 1984;105:114–121. doi: 10.1016/s0076-6879(84)05015-1. [DOI] [PubMed] [Google Scholar]
  22. Goormaghtigh E., Ruysschaert J. M. Anthracycline glycoside-membrane interactions. Biochim Biophys Acta. 1984 Sep 3;779(3):271–288. doi: 10.1016/0304-4157(84)90013-3. [DOI] [PubMed] [Google Scholar]
  23. Hamada H., Okochi E., Watanabe M., Oh-hara T., Sugimoto Y., Kawabata H., Tsuruo T. Mr 85,000 membrane protein specifically expressed in adriamycin-resistant human tumor cells. Cancer Res. 1988 Dec 15;48(24 Pt 1):7082–7087. [PubMed] [Google Scholar]
  24. Kanter P. M., Schwartz H. S. A fluorescence enhancement assay for cellular DNA damage. Mol Pharmacol. 1982 Jul;22(1):145–151. [PubMed] [Google Scholar]
  25. Kartner N., Evernden-Porelle D., Bradley G., Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. 1985 Aug 29-Sep 4Nature. 316(6031):820–823. doi: 10.1038/316820a0. [DOI] [PubMed] [Google Scholar]
  26. Kees U. R. Resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment childhood lymphoblastic leukemia: isolation of a drug resistant and a sensitive cell line. Cancer Res. 1987 Jun 15;47(12):3088–3091. [PubMed] [Google Scholar]
  27. Kessel D., Wheeler C. m-AMSA as a probe for transport phenomena associated with anthracycline resistance. Biochem Pharmacol. 1984 Apr 1;33(7):991–993. doi: 10.1016/0006-2952(84)90505-7. [DOI] [PubMed] [Google Scholar]
  28. Krishan A., Sauerteig A., Gordon K. Effect of amphotericin B on Adriamycin transport in P388 cells. Cancer Res. 1985 Sep;45(9):4097–4102. [PubMed] [Google Scholar]
  29. Merry S., Fetherston C. A., Kaye S. B., Freshney R. I., Plumb J. A. Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil. Br J Cancer. 1986 Jan;53(1):129–135. doi: 10.1038/bjc.1986.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moscow J. A., Cowan K. H. Multidrug resistance. J Natl Cancer Inst. 1988 Mar 2;80(1):14–20. doi: 10.1093/jnci/80.1.14. [DOI] [PubMed] [Google Scholar]
  31. Per S. R., Mattern M. R., Mirabelli C. K., Drake F. H., Johnson R. K., Crooke S. T. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Mol Pharmacol. 1987 Jul;32(1):17–25. [PubMed] [Google Scholar]
  32. Pommier Y., Kerrigan D., Schwartz R. E., Swack J. A., McCurdy A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res. 1986 Jun;46(6):3075–3081. [PubMed] [Google Scholar]
  33. Preston R. J. The use of inhibitors of DNA-repair in the study of the mechanisms of induction of chromosome aberrations. Cytogenet Cell Genet. 1982;33(1-2):20–26. doi: 10.1159/000131721. [DOI] [PubMed] [Google Scholar]
  34. Robson C. N., Hoban P. R., Harris A. L., Hickson I. D. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines. Cancer Res. 1987 Mar 15;47(6):1560–1565. [PubMed] [Google Scholar]
  35. Rowe T. C., Chen G. L., Hsiang Y. H., Liu L. F. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res. 1986 Apr;46(4 Pt 2):2021–2026. [PubMed] [Google Scholar]
  36. Seelig G. F., Meister A. Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. Methods Enzymol. 1985;113:379–390. doi: 10.1016/s0076-6879(85)13050-8. [DOI] [PubMed] [Google Scholar]
  37. Sekura R. D., Duffel M. W., Jakoby W. B. Aryl sulfotransferases. Methods Enzymol. 1981;77:197–206. doi: 10.1016/s0076-6879(81)77026-5. [DOI] [PubMed] [Google Scholar]
  38. Shen D. W., Fojo A., Chin J. E., Roninson I. B., Richert N., Pastan I., Gottesman M. M. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science. 1986 May 2;232(4750):643–645. doi: 10.1126/science.3457471. [DOI] [PubMed] [Google Scholar]
  39. Shoemaker D. D., Cysyk R. L., Gormley P. E., DeSouza J. J., Malspeis L. Metabolism of 4'-(9-acridinylamino)methanesulfon-m-anisidide by rat liver microsomes. Cancer Res. 1984 May;44(5):1939–1945. [PubMed] [Google Scholar]
  40. Shoemaker R. H., Curt G. A., Carney D. N. Evidence for multidrug-resistant cells in human tumor cell populations. Cancer Treat Rep. 1983 Oct;67(10):883–888. [PubMed] [Google Scholar]
  41. Sinha B. K., Katki A. G., Batist G., Cowan K. H., Myers C. E. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells. Biochem Pharmacol. 1987 Mar 15;36(6):793–796. doi: 10.1016/0006-2952(87)90164-x. [DOI] [PubMed] [Google Scholar]
  42. Snow K., Judd W. Heterogeneity of a human T-lymphoblastoid cell line. Exp Cell Res. 1987 Aug;171(2):389–403. doi: 10.1016/0014-4827(87)90171-6. [DOI] [PubMed] [Google Scholar]
  43. Streeter D. G., Johl J. S., Gordon G. R., Peters J. H. Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells. Cancer Chemother Pharmacol. 1986;16(3):247–252. doi: 10.1007/BF00293986. [DOI] [PubMed] [Google Scholar]
  44. Strobel H. W., Dignam J. D. Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol. 1978;52:89–96. doi: 10.1016/s0076-6879(78)52009-0. [DOI] [PubMed] [Google Scholar]
  45. Tsuruo T. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics. Cancer Treat Rep. 1983 Oct;67(10):889–894. [PubMed] [Google Scholar]
  46. Van der Bliek A. M., Meyers M. B., Biedler J. L., Hes E., Borst P. A 22-kd protein (sorcin/V19) encoded by an amplified gene in multidrug-resistant cells, is homologous to the calcium-binding light chain of calpain. EMBO J. 1986 Dec 1;5(12):3201–3208. doi: 10.1002/j.1460-2075.1986.tb04630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Vasanthakumar G., Ahmed N. K. Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells. Cancer Chemother Pharmacol. 1986;18(2):105–110. doi: 10.1007/BF00262277. [DOI] [PubMed] [Google Scholar]
  48. Vosberg H. P. DNA topoisomerases: enzymes that control DNA conformation. Curr Top Microbiol Immunol. 1985;114:19–102. doi: 10.1007/978-3-642-70227-3_2. [DOI] [PubMed] [Google Scholar]
  49. Warholm M., Guthenberg C., von Bahr C., Mannervik B. Glutathione transferases from human liver. Methods Enzymol. 1985;113:499–504. doi: 10.1016/s0076-6879(85)13065-x. [DOI] [PubMed] [Google Scholar]
  50. Yanovich S., Taub R. N. Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy. Cancer Res. 1983 Sep;43(9):4167–4171. [PubMed] [Google Scholar]
  51. Zwelling L. A. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev. 1985;4(4):263–276. doi: 10.1007/BF00048092. [DOI] [PubMed] [Google Scholar]
  52. Zwelling L. A., Kerrigan D., Michaels S., Kohn K. W. Cooperative sequestration of m-AMSA in L1210 cells. Biochem Pharmacol. 1982 Oct 15;31(20):3269–3277. doi: 10.1016/0006-2952(82)90561-5. [DOI] [PubMed] [Google Scholar]
  53. Zwelling L. A., Michaels S., Erickson L. C., Ungerleider R. S., Nichols M., Kohn K. W. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. Biochemistry. 1981 Nov 10;20(23):6553–6563. doi: 10.1021/bi00526a006. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES